drugset / Trial / NCT01973842
Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients
Phase 2
Unknown
90 enrolled
Aristotle University Of Thessaloniki
Eugonia IVF Unit, Athens, Greece · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The present study aims to investigate whether the dosage of the GnRH agonist used for triggering final oocyte maturation affects the maturity of the oocytes retrieved in high risk for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and recombinant FSH.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Triptorelin | Other / unclassified | 0.1 mg | — |
| Comparator | Triptorelin | Other / unclassified | 0.2 mg | — |
| Comparator | Triptorelin | Other / unclassified | 0.4 mg | — |